TY - JOUR
T1 - MalDA, Accelerating Malaria Drug Discovery
AU - the Malaria Drug Accelerator Consortium
AU - Yang, Tuo
AU - Ottilie, Sabine
AU - Istvan, Eva S.
AU - Godinez-Macias, Karla P.
AU - Lukens, Amanda K.
AU - Baragaña, Beatriz
AU - Campo, Brice
AU - Walpole, Chris
AU - Niles, Jacquin C.
AU - Chibale, Kelly
AU - Dechering, Koen J.
AU - Llinás, Manuel
AU - Lee, Marcus C.S.
AU - Kato, Nobutaka
AU - Wyllie, Susan
AU - McNamara, Case W.
AU - Gamo, Francisco Javier
AU - Burrows, Jeremy
AU - Fidock, David A.
AU - Goldberg, Daniel E.
AU - Gilbert, Ian H.
AU - Wirth, Dyann F.
AU - Winzeler, Elizabeth A.
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/6
Y1 - 2021/6
N2 - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
AB - The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.
UR - http://www.scopus.com/inward/record.url?scp=85101721246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101721246&partnerID=8YFLogxK
U2 - 10.1016/j.pt.2021.01.009
DO - 10.1016/j.pt.2021.01.009
M3 - Review article
C2 - 33648890
AN - SCOPUS:85101721246
SN - 1471-4922
VL - 37
SP - 493
EP - 507
JO - Trends in Parasitology
JF - Trends in Parasitology
IS - 6
ER -